A multicentre, prospective, randomised, double-blind, placebo-controlled, international study to assess the effects of 2 g per day of strontium ranelate versus placebo on the time to fracture healing in osteoporotic men and women.

Trial Profile

A multicentre, prospective, randomised, double-blind, placebo-controlled, international study to assess the effects of 2 g per day of strontium ranelate versus placebo on the time to fracture healing in osteoporotic men and women.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Fracture healing
  • Sponsors IRIS
  • Most Recent Events

    • 29 Mar 2012 This trial has been completed in Germany and Hungary.
    • 22 Feb 2012 This trial has been completed in Czech Republic as reported by European Clinical Trials Database record.
    • 11 May 2011 Planned end date changed from 31 Jul 2011 to 31 Mar 2012 as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top